Candidemia

Summary

Candidemia (MONDO:0044070) is a disease and 48 clinical trials. Top therapeutic interventions include fluconazole, micafungin, and anidulafungin. A subtype of candidiasis, invasive — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 48

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	candidemia
Mondo ID	MONDO:0044070
MeSH	D058387
SNOMED CT	432261003
UMLS	C0877445
MedGen	163760
GARD	0025878
Is cancer (heuristic)	no

Also known as: candidemia · Candidemias

Disease family

This is a subtype of candidiasis, invasive. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › opportunistic mycosis › candidiasis › candidiasis, invasive › candidemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Anidulafungin	Approved (phase 4)
Voriconazole	Approved (phase 4)
Caspofungin	Phase 3 (in late-stage trials)
Fluconazole	Phase 3 (in late-stage trials)
Fosmanogepix	Phase 3 (in late-stage trials)
INTERFERON GAMMA-1B	Phase 3 (in late-stage trials)
Ibrexafungerp	Phase 3 (in late-stage trials)
Isavuconazole	Phase 3 (in late-stage trials)
Micafungin	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 48.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	21
PHASE3	13
PHASE4	6
PHASE2	6
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00548262	PHASE4	COMPLETED	This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis
NCT00670657	PHASE4	COMPLETED	CRITIC - Treatment of Candidemia and Invasive Candidiasis
NCT00839540	PHASE4	COMPLETED	Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
NCT00940017	PHASE4	COMPLETED	A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
NCT01734525	PHASE4	COMPLETED	Negative Beta Glucan in ICU Patients
NCT01982071	PHASE4	TERMINATED	A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
NCT05421858	PHASE3	RECRUITING	A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT06859671	PHASE3	NOT_YET_RECRUITING	A Randomized Study of a Short Duration Therapy for Candidemia
NCT00105144	PHASE3	COMPLETED	Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
NCT00189709	PHASE3	COMPLETED	Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia
NCT00413218	PHASE3	COMPLETED	Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
NCT00537329	PHASE3	COMPLETED	Anidulafungin In Treatment Of Candidemia In Asian Subjects
NCT00761267	PHASE3	COMPLETED	Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
NCT01176058	PHASE3	TERMINATED	A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis
NCT01270490	PHASE3	UNKNOWN	Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia
NCT03363841	PHASE3	COMPLETED	Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
NCT03667690	PHASE3	COMPLETED	Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
NCT04368559	PHASE3	COMPLETED	Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
NCT05178862	PHASE3	TERMINATED	A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
NCT04979052	PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
NCT00739934	PHASE2	COMPLETED	Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection
NCT02244606	PHASE2	COMPLETED	Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
NCT02734862	PHASE2	COMPLETED	CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
NCT03604705	PHASE2	COMPLETED	An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
NCT04148287	PHASE2	COMPLETED	An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
NCT00607763	PHASE1	COMPLETED	Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
NCT00608335	PHASE1	COMPLETED	Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
NCT06907992	Not specified	NOT_YET_RECRUITING	A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia
NCT00113191	Not specified	COMPLETED	Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
NCT00802854	Not specified	COMPLETED	Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV
NCT00903526	Not specified	UNKNOWN	Prevalence and Epidemiology of Nosocomial Candidaemia and Antifungal Susceptibility Patterns in an Italian Tertiary-Care Hospital
NCT01174147	Not specified	COMPLETED	A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093)
NCT01213823	Not specified	TERMINATED	Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
NCT01249313	Not specified	UNKNOWN	Risk Factor and Outcome of Candidemia
NCT01281345	Not specified	COMPLETED	SIHAM Candidemia Network:An Observational Study
NCT01406093	Not specified	COMPLETED	Early- and Late-onset Candidemia
NCT01438216	Not specified	UNKNOWN	Anidulafungin Pharmacokinetics in Intensive Care Unit Patients
NCT01525095	Not specified	COMPLETED	Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
NCT01622595	Not specified	WITHDRAWN	UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
NCT01752166	Not specified	COMPLETED	Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUCONAZOLE	4	9
MICAFUNGIN	4	7
ANIDULAFUNGIN	4	6
CASPOFUNGIN	4	6
VORICONAZOLE	4	4
IBREXAFUNGERP	4	3
REZAFUNGIN	4	3
AMPHOTERICIN B	4	1
INTERFERON GAMMA-1B	4	1
POSACONAZOLE	4	1
FOSMANOGEPIX	3	3
INTERFERON GAMMA-1A	3	1
ISAVUCONAZOLE	3	1
CHEMBL3760049	0	6
CHEMBL4750941	0	6
CHEMBL499808	0	6
CHEMBL4743205	0	2
1,2,4-TRIAZOLE	0	1